Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15112753 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP2D6ALOX15KDM4E | |
| SCHEMBL15781119 | 0.78 | CYP1A2 (0.38) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL22200126 | 0.78 | TSHR (0.46) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL21107507 | 0.77 | KDM4E (0.43) | CYP1A2CYP2D6ALOX15KDM4EDRD2 | |
| SCHEMBL22848872 | 0.77 | KDM4E (0.39) | CYP1A2CYP2D6ALOX15KDM4EDRD2 | |
| SCHEMBL21733145 | 0.77 | KDM4E (0.39) | CYP1A2CYP2D6ALOX15KDM4EDRD2 | |
| SCHEMBL14942381 | 0.77 | KDM4E (0.42) | CYP1A2CYP2D6ALOX15KDM4EDRD2 | |
| SCHEMBL25935795 | 0.76 | CYP1A2 (0.39) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24673601 | 0.76 | KDM4E (0.38) | CYP1A2CYP2D6ALOX15KDM4EDRD2 | |
| SCHEMBL24764885 | 0.74 | KDM4E (0.37) | KDM4EDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | CYP1A2 3232/4885CYP2D6 4042/4885ALOX15 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.